Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

5th World Congress on Cancer Therapy

Atlanta, USA

Xiaoliang X. Xu

Zhongshan University, China

Title: TRB2-SKP2 signaling and SKP2 targeted therapy in human retinoblastoma and related tumors

Biography

Biography: Xiaoliang X. Xu

Abstract

Retinoblastomas initiate in response to biallelic RB1 inactivation and loss of functional Rb protein in cone precursors, yet the cellular circuitry that sensitizes to Rb loss have been unclear. Previous studies showed that retinoblastomas exhibit cone precursor properties and depend on cone-specifi c thyroid hormone receptor 2 (TR2) and SKP2 signaling. Here, we show that TR2 promotes SKP2 expression by antagonizing TR1, which enables Emi1-dependent inhibition of APC/CCdh1- mediated SKP2 degradation. TR2 also antagonized TR1-mediated suppression of anterior pituitary tumors in Rb1+/- mice. Moreover, in certain RB1-wild type tumors, Rb appears to have a function similar to TR2, since phospho-Rb sustained Emi1 and SKP2 activity by suppressing TR1. While both TR1 and TR2 associated with phospho-Rb, Emi1, and SKP2, only TR1 suppressed SKP2 expression. Th ese results suggest that loss of RB1, and the resulting loss of phospho-Rb, enables TR1-dependent suppression of Emi1 and SKP2, as a safeguard against RB1-defi cient tumor formation. TR2 counteracts TR1, thus disrupting this safeguard and enabling the development of RB1-defi cient tumors. SKP2-KD caused apoptosis of retinoblastoma, Rb defi cient myxofi brosarcoma and small cell lung cancer cells (SCLC), indicating that SKP2 is a synthetic lethal gene in retinoblastoma and other Rb defi cient cancers. Targeted therapy by SKP2 inhibitor C1 signifi cantly suppressed retinoblastoma, SCLC, and myxofi brosarcoma tumor growth by suppressing SKP2 activity and promoting p27 accumulation in vitro and in vivo.